< Back to previous page
Patent
Cell therapy for myelodysplastic syndromes
The invention provides methods for treating myelodysplasia syndrome (MDS). The invention is generally directed to reducing certain overt symptoms and disease-causing biological events in MDS by administering certain cells to a subject having MDS. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to affect these events. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for affecting these events.
Patent Publication Number: EP2992088
Year filing: 2019
Year approval: 2019
Year publication: 2019
Status: Assigned
URI: link to Espacenet
Technology domains: Analysis of biological materials, Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven